GHK-Cu + BPC-157 common uses, half-life, side effects and more

This pairing puts GHK-Cu together with BPC-157 for skin and soft-tissue repair. GHK-Cu is a copper tripeptide used for skin, hair, and cosmetic repair. BPC-157 is a synthetic pentadecapeptide used for tendon, ligament, muscle, joint, wound, and gut recovery. People inject the two for skin quality, soft-tissue repair, post-procedure recovery, scar remodeling, and injury recovery. They usually run them as separate vials. A two-component premix exists at one vendor but is uncommon. The same pair is more often bought pre-mixed inside the larger GLOW and KLOW blends. Topical GHK-Cu is a cosmetic ingredient. The injectable pairing is a gray-market research-only product.

• Skin quality and cosmetic recovery
• Post-procedure recovery after microneedling, laser, or minor procedures
• Scar remodeling and wound healing
• Tendon, ligament, muscle, and joint recovery
• Hair and scalp appearance
• Soft-tissue repair

Once daily or every other day in 4 to 8 week cycles

People most often run this pair as two separate vials and dose each on its own schedule. GHK-Cu is injected at 1 to 2 mg subcutaneously daily. BPC-157 is injected at 250 to 500 mcg subcutaneously once or twice daily. Cosmetic and recovery cycles usually run 4 to 8 weeks. A single-vendor two-component premix holds 50 mg GHK-Cu and 10 mg BPC-157 at a 5:1 ratio by mass. Dosing that rare premix by the GHK-Cu amount at 1 to 2 mg delivers 200 to 400 mcg BPC-157 per injection. That amount lands at the low-to-middle of the standalone BPC-157 range of 250 to 500 mcg. The pair is more often bought pre-mixed inside the GLOW blend. That product also carries TB-500.

• Assembling the pair from two separate vials keeps each peptide on its own dose and schedule
• GHK-Cu is often cycled 30 days on and 30 days off to limit copper exposure
• GLOW and KLOW add further peptides beyond this pair and should not be logged as this two-peptide pairing

No combination pharmacokinetic study exists. The components clear at different rates. BPC-157 clears from animal plasma in under 30 minutes and has no human measurement. Injected GHK-Cu has no measured human plasma half-life by any route.

GHK-Cu solution is normally blue to blue-violet from the copper complex. A loss of that blue color can signal degradation. Strong chelators such as EDTA can disrupt the copper complex.

• Injection-site redness, swelling, bruising, soreness, or pain that can begin hours after the shot
• Skin stinging, redness, itching, or contact dermatitis from topical GHK-Cu products
• Breakouts, headache, nausea, dizziness, fatigue, lightheadedness, or gastrointestinal upset reported by users
• Shortness of breath, gum darkening, or skin darkening in rare FDA reports that also involved other peptides
• Copper excess can cause abdominal pain, nausea, vomiting, jaundice, unusual bruising, or anemia

• GHK-Cu

  1 to 2 mg per daily subcutaneous injection

• BPC-157

  250 to 500 mcg per subcutaneous injection once or twice daily

GHK-Cu is the tripeptide GHK bound to copper. Copper is a required cofactor for two enzymes. Lysyl oxidase cross-links collagen and elastin. Superoxide dismutase defends cells against oxidation. Skin and wound-cell models link GHK-Cu to fibroblast activity, keratinocyte activity, extracellular-matrix turnover, and inflammatory signaling. BPC-157 has no identified receptor and no settled human mechanism. Animal and cell work reports that it raises the receptor VEGFR2 without raising VEGF-A itself, raises nitric-oxide signaling, and moves tendon fibroblasts. Its effect on new blood vessels runs in both directions across tissues rather than in one. The stated rationale for the pair is matrix remodeling from GHK-Cu alongside repair signaling from BPC-157. No study shows the combination outperforms either peptide alone.

Direct evidence for the GHK-Cu plus BPC-157 combination is very low. No human trial, animal study, pharmacokinetic study, or case series of the pair was found. GHK-Cu has route-specific evidence that is strongest for topical cosmetic and wound use. Injected GHK-Cu has no comparable human efficacy or pharmacokinetic base and has never been given to a person in a published study. BPC-157 evidence is mostly animal and cell work with minimal uncontrolled human musculoskeletal data. No completed and fully published human efficacy trial exists for BPC-157 in injury recovery. Most BPC-157 research traces to a single group with little independent replication. The 50/10 mg blend ratio comes from the market rather than from any dose-finding study.

• BPC-157 is banned in sport at all times under WADA section S0 so tested athletes should treat the whole blend as prohibited
• The injectable blend is not FDA approved and FDA has flagged injectable GHK-Cu and BPC-157 in compounding for limited human safety, immunogenicity, and peptide-impurity concerns
• People with active or recent cancer, unexplained masses, or proliferative retinopathy should avoid the blend because BPC-157 has no carcinogenicity study and the blend's repair and matrix-remodeling signals are untested in those settings
• Wilson disease, copper overload, significant liver or kidney disease, unexplained anemia, or copper allergy make injected GHK-Cu riskier because a needle bypasses the gut limits on copper
• Blood thinners, clotting disorders, or abnormal liver markers need clinician guidance because animal BPC-157 studies found clotting-time and liver-marker changes
• Pregnancy, breastfeeding, fertility, pediatric use, and long-term repeated cycles have no adequate safety data for either component